James Hambro & Partners LLP purchased a new position in shares of Insulet Co. (NASDAQ:PODD – Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 915 shares of the medical instruments supplier’s stock, valued at approximately $213,000.
Several other institutional investors also recently modified their holdings of PODD. Revolve Wealth Partners LLC acquired a new position in Insulet during the third quarter valued at approximately $368,000. Chicago Capital LLC boosted its holdings in shares of Insulet by 3.4% in the third quarter. Chicago Capital LLC now owns 168,434 shares of the medical instruments supplier’s stock valued at $39,203,000 after buying an additional 5,557 shares during the period. Raymond James & Associates boosted its holdings in shares of Insulet by 3.8% in the third quarter. Raymond James & Associates now owns 37,456 shares of the medical instruments supplier’s stock valued at $8,718,000 after buying an additional 1,367 shares during the period. Blue Trust Inc. boosted its holdings in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Insulet by 3.0% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,453 shares of the medical instruments supplier’s stock valued at $1,502,000 after buying an additional 188 shares during the period.
Insulet Stock Performance
NASDAQ PODD traded down $0.73 on Monday, hitting $235.86. 118,374 shares of the stock were exchanged, compared to its average volume of 794,159. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. The business’s fifty day moving average is $218.20 and its 200 day moving average is $197.05. Insulet Co. has a 52 week low of $128.68 and a 52 week high of $243.98. The company has a market capitalization of $16.54 billion, a PE ratio of 43.02, a P/E/G ratio of 4.35 and a beta of 1.21.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the stock. BTIG Research upped their price target on shares of Insulet from $250.00 to $260.00 and gave the company a “buy” rating in a report on Monday, October 14th. Raymond James upped their price target on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Barclays upped their price target on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Canaccord Genuity Group boosted their price objective on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Citigroup boosted their price objective on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $242.29.
Read Our Latest Report on Insulet
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
See Also
- Five stocks we like better than Insulet
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Canada Bond Market Holiday: How to Invest and Trade
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Stock Analyst Ratings and Canadian Analyst Ratings
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD – Free Report).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.